Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer Export

@article{citeulike:3558624, abstract = {PurposeBone loss resulting from the treatment of breast and prostate cancer is an emerging problem. Bisphosphonates have a potential role in the prevention of this cancer treatment-induced bone loss (CTIBL). MethodsStudies evaluating the incidence and prevalence of CTIBL in early breast and prostate cancer patients and trials evaluating the preventative role of bisphosphonates were identified by a search of the PubMed and Cochrane Library databases through the end of March 2008. Reference lists from retrieved articles were cross referenced, and further information was obtained from relevant scientific meetings. ResultsSeveral therapies commonly used in the treatment of women and men with breast and prostate cancers, in particular the aromatase inhibitors (AIs) for breast cancer and androgen deprivation therapy (ADT) for prostate cancer, are associated with significant bone loss and with an increase in fracture risk. The use of bisphosphonates seems to attenuate the bone loss, although the long-term impact remains unclear because of insufficient follow-up. ConclusionAdjuvant endocrine therapy with an AI or androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy. Clear identification of risk factors for osteoporosis in individual patients should aid treatment decisions about whether to use bisphosphonates when starting or switching to an AI or ADT. Patients need to be educated about this risk and other measures to avoid this complication, including lifestyle modifications that may benefit their general and bone health. 10.1200/JCO.2008.18.4184}, author = {Saad, Fred and Adachi, Jonathan D. and Brown, Jacques P. and Canning, Leah A. and Gelmon, Karen A. and Josse, Robert G. and Pritchard, Kathleen I.}, citeulike-article-id = {3558624}, citeulike-linkout-0 = {http://dx.doi.org/10.1200/JCO.2008.18.4184}, citeulike-linkout-1 = {http://jco.ascopubs.org/cgi/content/abstract/26/33/5465}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/18955443}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=18955443}, day = {20}, doi = {10.1200/JCO.2008.18.4184}, journal = {J Clin Oncol}, keywords = {aromatase, bone, breast, cancer, inhibitor, loss, prostate}, month = {November}, number = {33}, pages = {5465--5476}, posted-at = {2008-11-17 15:01:05}, priority = {2}, title = {Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer}, url = {http://dx.doi.org/10.1200/JCO.2008.18.4184}, volume = {26}, year = {2008} }

TY - JOUR ID - citeulike:3558624 L3 - citeulike-article-id:3558624 N2 - PurposeBone loss resulting from the treatment of breast and prostate cancer is an emerging problem. Bisphosphonates have a potential role in the prevention of this cancer treatment-induced bone loss (CTIBL). MethodsStudies evaluating the incidence and prevalence of CTIBL in early breast and prostate cancer patients and trials evaluating the preventative role of bisphosphonates were identified by a search of the PubMed and Cochrane Library databases through the end of March 2008. Reference lists from retrieved articles were cross referenced, and further information was obtained from relevant scientific meetings. ResultsSeveral therapies commonly used in the treatment of women and men with breast and prostate cancers, in particular the aromatase inhibitors (AIs) for breast cancer and androgen deprivation therapy (ADT) for prostate cancer, are associated with significant bone loss and with an increase in fracture risk. The use of bisphosphonates seems to attenuate the bone loss, although the long-term impact remains unclear because of insufficient follow-up. ConclusionAdjuvant endocrine therapy with an AI or androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy. Clear identification of risk factors for osteoporosis in individual patients should aid treatment decisions about whether to use bisphosphonates when starting or switching to an AI or ADT. Patients need to be educated about this risk and other measures to avoid this complication, including lifestyle modifications that may benefit their general and bone health. 10.1200/JCO.2008.18.4184 IS - 33 JF - J Clin Oncol EP - 5476 TI - Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer VL - 26 SP - 5465 KW - aromatase KW - bone KW - breast KW - cancer KW - inhibitor KW - loss KW - prostate AU - Saad, Fred AU - Adachi, Jonathan AU - Brown, Jacques AU - Canning, Leah AU - Gelmon, Karen AU - Josse, Robert AU - Pritchard, Kathleen PY - 2008/11/20/ UR - http://dx.doi.org/10.1200/JCO.2008.18.4184 ER -